Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer

被引:16
作者
Yuan, Hang [1 ]
Zheng, Bo'an [1 ]
Tu, Shiliang [1 ]
机构
[1] Zhejiang Prov Peoples Hosp, Surg Dept Coloproctol, Hangzhou 310014, Zhejiang, Peoples R China
关键词
Sustained-release; 5-fluorouracil; Colorectal cancer; Safety; Long-term effect; ADJUVANT REGIONAL CHEMOTHERAPY; ADVANCED GASTRIC-CANCER; PROGNOSTIC-SIGNIFICANCE; PANCREATIC-CANCER; NODE METASTASES; BREAST-CANCER; PHASE-II; CARCINOMA; TRIAL; 5-FU;
D O I
10.1186/s12957-015-0737-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The objective of this study was to investigate the safety and long-term clinical effect of intraperitoneal implantation of sustained-release 5-fluorouracil in patients with advanced colorectal cancer during radical resection. Methods: A total of 202 patients with advanced colorectal cancer undergoing radical operations were randomly divided into an experimental group (98 cases, intraoperative intraperitoneal implantation of sustained-release 5-fluorouracil 600 mg as local chemotherapy) and a control group (104 cases, without local chemotherapy). The clinical data of the two groups was compared including toxicity, complications, local recurrence rate, distant metastasis, disease-free survival, and 1-, 3-, and 5-year survival rates. Results: Both groups of patients were followed up for more than 5 years, the longest follow-up time was 7.5 years. Bone marrow suppression, hepato-renal function, postoperative anastomotic leakage, pelvic effusion, incision infection, the incidence of intestinal obstruction, venting time, and hospital stay after operation (days) between two groups had no statistical significant difference. Locoregional recurrence and liver metastasis rate were decreased significantly in experimental group (P = 0.04 and 0.04). Extensive peritoneal metastasis and other organ metastasis rates had no significant difference between two groups. In the experimental group, 1-, 3-, and 5-year survival rates were higher than in the control group (95.92 vs 87.50 %, 77.55 vs 64.42 %, and 56.12 vs 40.38 %), which had significant difference. Disease-free survival (DFS) of the experimental group was higher than that of the control group (chi(2) = 5.00, P = 0.025). Conclusions: Intraperitoneal implantation of sustained-release 5-fluorouracil is safe for advanced colorectal cancer during radical resection, which can reduce locoregional recurrence rate and liver metastasis rate. The long-term efficacy was reliable, and long-term survival and disease-free survival rate can be improved.
引用
收藏
页数:10
相关论文
共 26 条
[1]   Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma [J].
Alexander, H. Richard, Jr. ;
Bartlett, David L. ;
Pingpank, James F. ;
Libutti, Steven K. ;
Royal, Richard ;
Hughes, Marybeth S. ;
Holtzman, Matthew ;
Hanna, Nader ;
Turner, Keli ;
Beresneva, Tatiana ;
Zhu, Yue .
SURGERY, 2013, 153 (06) :779-786
[2]  
Chen Wan-Ping, 2006, Hepatobiliary Pancreat Dis Int, V5, P391
[3]   Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial [J].
Davis, Jeremy L. ;
Pandalai, Prakash ;
Ripley, R. Taylor ;
Langan, Russell C. ;
Steinberg, Seth M. ;
Walker, Melissa ;
Toomey, Mary Ann ;
Levy, Elliot ;
Avital, Itzhak .
TRIALS, 2011, 12
[4]   OCCULT REGIONAL LYMPH-NODE METASTASES FROM BREAST-CARCINOMA - IMMUNOHISTOLOGICAL DETECTION WITH ANTIBODIES CAM 5.2 AND NCRC-11 [J].
GALEA, MH ;
ATHANASSIOU, E ;
BELL, J ;
DILKS, B ;
ROBERTSON, JFR ;
ELSTON, CW ;
BLAMEY, RW ;
ELLIS, IO .
JOURNAL OF PATHOLOGY, 1991, 165 (03) :221-227
[5]  
Guo W, 2015, ASIAN PAC J CANCER P, V1, P407
[6]  
GYVES J, 1985, SEMIN ONCOL, V12, P29
[7]   DETECTION AND SIGNIFICANCE OF OCCULT METASTASES IN NODE-NEGATIVE BREAST-CANCER [J].
HAINSWORTH, PJ ;
TJANDRA, JJ ;
STILLWELL, RG ;
MACHET, D ;
HENDERSON, MA ;
RENNIE, GC ;
MCKENZIE, IFC ;
BENNETT, RC .
BRITISH JOURNAL OF SURGERY, 1993, 80 (04) :459-463
[8]   Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer [J].
Hu, Xiu-Feng ;
Yao, Jun ;
Gao, She-Gan ;
Wang, Xin-Shuai ;
Peng, Xiu-Qing ;
Yang, Yan-Tong ;
Feng, Xiao-Shan .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) :5231-5235
[9]  
Huang B, 2013, BMC CANCER, V4, P13
[10]   Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival [J].
Jarnagin, W. R. ;
Schwartz, L. H. ;
Gultekin, D. H. ;
Gonen, M. ;
Haviland, D. ;
Shia, J. ;
D'Angelica, M. ;
Fong, Y. ;
DeMatteo, R. ;
Tse, A. ;
Blumgart, L. H. ;
Kemeny, N. .
ANNALS OF ONCOLOGY, 2009, 20 (09) :1589-1595